The 2016 revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provides updated recommendations for the treatment of allergic rhinitis. The revision addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists alone or in combination. The guidelines offer specific recommendations for treatment choice, rationale, and considerations for clinicians and patients. The ARIA panel emphasizes that appropriate treatment can improve patients' quality of life, school and work productivity. The guidelines are intended to support patients, caregivers, and healthcare providers in making informed decisions about treatment options. The revision includes new evidence and updates to existing recommendations, following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The ARIA 2016 revision aims to enhance the management of allergic rhinitis and improve patient outcomes.The 2016 revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provides updated recommendations for the treatment of allergic rhinitis. The revision addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists alone or in combination. The guidelines offer specific recommendations for treatment choice, rationale, and considerations for clinicians and patients. The ARIA panel emphasizes that appropriate treatment can improve patients' quality of life, school and work productivity. The guidelines are intended to support patients, caregivers, and healthcare providers in making informed decisions about treatment options. The revision includes new evidence and updates to existing recommendations, following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The ARIA 2016 revision aims to enhance the management of allergic rhinitis and improve patient outcomes.